Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029
세계의 마이크로플루이딕스 시장 규모는 2024년 224억 3,000만 달러로 평가되었고, 2029년까지 326억 7,000만 달러에 이를 것으로 예측되며, 예측 기간에 CAGR로 7.8%의 성장이 예상됩니다.
시장은 많은 심각한 요인으로 확대되고 있습니다. POC(Point of Care) 진단에 대한 요구 증가는 주요 요인 중 하나입니다. 암과 당뇨병과 같은 만성 질환 증가는 신속하고 정확한 진단의 필요성을 증가시키고 있으며, 이는 의료에서 마이크로플루이딕스의 이용을 촉진하고 있습니다. 또한 약물전달, 장기 칩 기술, 맞춤형 의료 등의 혁신으로 마이크로플루이딕스 디바이스의 사용이 증가하고 있습니다. 또한, 단백질체학와 유전체학와 관련된 연구 증가도 시장을 견인하고 있습니다.
| 조사 범위 |
| 조사 대상년도 |
2022-2029년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
100만 달러/10억 달러 |
| 부문 |
제품별, 용도별, 최종 사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
'폴리머가 2023년 최대 시장 점유율을 차지했습니다.'
마이크로플루이딕스 시장은 저비용, 생산의 용이성 및 적응성에서 중합체에 의해 추진되고 있습니다. 마이크로플루이딕스 디바이스의 제조에는 폴리디메틸실록산(PDMS), 폴리메틸메타크릴레이트(PMMA), 고리형 올레핀 공중합체(COC) 등의 폴리머가 필요하게 됩니다. 이 폴리머는 마이크로채널과 구조를 만드는 데 도움이 됩니다. 게다가 실리콘이나 유리와 같은 종래의 재료에 비해 폴리머는 성형이 용이하고 제조 비용도 저렴합니다. 폴리머의 생체적합성은 약물 전달, 실험실 칩, 진단과 같은 다양한 의료 용도에 유용합니다. 이러한 이점으로부터, 마이크로플루이딕스 시장에서는 폴리머가 최대의 점유율을 차지하고 있습니다.
'병원 및 진단센터가 예측기간에 시장에서 가장 높은 성장률을 기록합니다.'
다양한 주요 요인이 마이크로플루이딕스 산업에서 병원 및 진단센터의 성장을 가속하고 있습니다. 주요 요인 중 하나는 POC(Point of Care) 진단에 대한 요구 증가입니다. POC(Point of Care) 진단은 환자의 결과를 개선하는 신속한 현장 검사를 제공하기 때문입니다. 마이크로플루이딕스는 보다 빠르고 정확한 결과를 제공하기 때문에 이 선호되는 결과에 큰 역할을 합니다. 또한 COVID-19와 같은 감염증 증가로 임상 현장에서 효율적인 진단에 대한 요구가 높아지고 있습니다. 이 장비는 비용을 절감하고 검사 방법을 가속화하며 진단의 정확성과 정확성을 향상시킵니다.
'예측 기간에 아시아태평양이 시장에서 가장 높은 성장률을 기록합니다.'
2024년부터 2029년까지 예측기간을 통해 아시아태평양이 가장 높은 CAGR을 기록합니다. 혁신 기술에 대한 수요는 특히 중국, 인도, 일본에서 증가하고 있습니다. 진단 및 치료 용도를 위한 마이크로플루이딕스 디바이스는 만성 질환과 감염의 유행, 조기 진단 및 예방 의료에 대한 주목 증가에 의해 사용되고 있습니다. 이 지역의 제약산업과 생명과학산업도 연구개발활동을 하고 있으며, 개별화의료나 창약에 있어서 마이크로플루이딕스에 대한 요구가 높아지고 있습니다.
본 보고서에서는 세계의 마이크로플루이딕스 시장에 대해 조사 분석하여 주요 촉진요인과 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
- 마이크로플루이딕스 시장 개요
- 아시아태평양의 마이크로플루이딕스 시장 : 최종 사용자별 및 국가별(2023년)
- 마이크로플루이딕스 시장 : 지역별
- 마이크로플루이딕스 시장의 지리적 스냅샷
제5장 시장 개요
- 서문
- 시장 역학
- 산업 동향
- e건강 진단
- 마이크로플루이딕스와 3D 프린팅의 통합
- 제품 개발에 대한 연구개발 투자
- Porter's Five Forces 분석
- 주요 이해관계자와 구매 기준
- 규제 상황
- 북미
- 유럽
- 아시아태평양
- 규제기관, 정부기관, 기타 조직
- 상환 시나리오
- 생태계 분석
- 밸류체인 분석
- 연구개발
- 원재료 조달 및 제조
- 마케팅 판매, 유통 및 애프터 서비스
- 공급망 분석
- 고객의 비즈니스에 영향을 미치는 동향 및 혼란
- 마이크로플루이딕스 시장에 대한 생성형 AI의 영향
- 특허 분석
- 마이크로플루이딕스의 특허 공보의 동향
- 인사이트 : 관할과 상위 신청자의 분석
- 무역 분석
- 수입 데이터
- 수출 데이터(HS 코드 3822)
- 수출 데이터(HS 코드 8479)
- 기술 분석
- 주요 회의 및 이벤트
- 가격 분석
- 평균 판매 가격의 동향 : 지역별
- 상위 3 용도의 평균 판매 가격 : 주요 기업별
- 언멧 니즈 및 최종 사용자의 기대
- 사례 연구 분석
- 투자 및 자금조달 시나리오
제6장 마이크로플루이딕스 시장 : 제품별
- 서문
- 마이크로플루이딕스 디바이스
- 마이크로플루이딕스 컴포넌트
제7장 마이크로플루이딕스 시장 : 용도별
- 서문
- IVD
- 임상 진단
- 포인트 오브 케어 검사(POCT)
- 동물의학 진단
- 제약 및 생명 과학 연구
- 실험실 분석
- 마이크로 디스펜싱
- 마이크로 리액터
- 치료
제8장 마이크로플루이딕스 시장 : 최종 사용자별
- 서문
- 병원 및 진단센터
- 학술기관 및 연구기관
- 제약 및 바이오테크놀러지 기업
제9장 마이크로플루이딕스 시장 : 지역별
- 서문
- 북미
- 유럽
- 유럽의 거시 경제 전망
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시 경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시 경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동 및 아프리카
- 중동 및 아프리카의 거시 경제 전망
- GCC 국가
- 기타 중동 및 아프리카
제10장 경쟁 구도
- 서문
- 주요 진입기업의 전략 및 강점
- 마이크로플루이딕스 시장의 주요 참가 기업이 채용한 전략의 개요
- 수익 분석(2019-2023년)
- 시장 점유율 분석(2023년)
- 주요 시장 기업의 순위
- 기업 평가 매트릭스 : 주요 기업(2023년)
- 기업의 평가 매트릭스 : 스타트업 및 중소기업(2023년)
- 기업 평가 및 재무 지표
- 브랜드 및 제품 비교 분석
- 경쟁 시나리오
제11장 기업 프로파일
- 주요 기업
- DANAHER CORPORATION
- ILLUMINA, INC.
- BIOMERIEUX
- THERMO FISHER SCIENTIFIC INC.
- ABBOTT LABORATORIES
- PARKER HANNIFIN CORP
- SMC CORPORATION
- IDEX CORPORATION
- FORTIVE
- REVVITY, INC.
- AGILENT TECHNOLOGIES, INC.
- BIO-RAD LABORATORIES, INC.
- BECTON, DICKINSON AND COMPANY
- F. HOFFMANN-LA ROCHE LTD.
- STANDARD BIOTOOLS
- QUIDELORTHO CORPORATION
- HOLOGIC, INC.
- AIGNEP SPA
- DOLOMITE MICROFLUIDICS
- ELVEFLOW
- 기타 기업
- NANOSTRING TECHNOLOGIES
- INNOVATIVE BIOCHIPS, LLC
- FLUIDIC ANALYTICS
- UFLUIDIX
- HORIBA
- MICRONIT BV
- EMULATE INC.
- SPHERE FLUIDICS LIMITED
- ZEON CORPORATION
- QIAGEN NV
제12장 부록
AJY
The Microfluidics market is projected to reach USD 32.67 Billion by 2029 from USD 22.43 Billion in 2024, growing at a CAGR of 7.8% during the forecast period. The market for microfluidics is expanding due to a number of important factors. The growing requirement for point-of-care diagnostics is one of an important factor. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like cancer and diabetes, which is propelling the application of microfluidics in healthcare. Furthermore, the use of microfluidic devices is increasing due to innovations in drug delivery , organ-on-a-chip technology, and personalized medicine. Additionally, the market is driven by the rise in proteomics and genomics associated research.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD Million/USD Billion) |
| Segments | By Product, Application, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
"Polymers to account for largest market share in 2023."
The market for microfluidics is propelled by polymers because of their their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also, enables cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers accounts for the largest share in the microfluidics market.
"Hospital and Diagnostic Centers to register highest growth rate in the market during the forecast period."
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.
"Asia Pacific to register highest growth rate in the market during the forecast period."
The highest CAGR was registered by the APAC region throughout the forecast period from 2024-2029. Asia Pacific comprise India, China, Japan, Australia, South Korea and RoAPAC. The demand for innovative technologies is increasing, especially in China, India, and Japan. Microfluidic devices for diagnostic and therapeutic applications are used due to the rise in prevalence of chronic and infectious diseases and the increase in focus on early diagnosis and preventative healthcare. The region's rising pharmaceutical and lifesciences industries are also undertaking research and development initiatives, which increases the requirement for microfluidics in personalized medicine and drug discovery.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
- By Designation: C-level-- 14%, Director-level-10%, and Others-76%
- By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World -8%.
Prominent players in this market are Abbott laboratories (US) , Agilent Technologies, Inc. (US), Aignep S.P.A (Italy), biomerieux (France), BD(US), Bio-Rad laboratories, Inc (US), Danaher Corporation (US), Illumina Inc. (US), Parker Hannifin Corporation (US), Thermo Fisher Scientific Inc. (US), SMC Corporation (Japan), Idex Corporation (US), Fortive Corporation (US), Perkinelmer, Inc. (US), F.Hoffmann-LA Roche Ltd (Switzerland), Standard Biotools Inc. (US), Quidelortho Corporation (US), Hologic Inc. (US), Dolomite Microfluidics (UK) and Elveflow (France).
Research Coverage
The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.
Key Benefits of Buying the Report:
The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.
The report provides the insights on the following pointers:
Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in number of diagnostic centers.
Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.
Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.
Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 MARKET STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.2 RESEARCH DESIGN
- 2.2.1 SECONDARY RESEARCH
- 2.2.1.1 Key data from secondary sources
- 2.2.2 PRIMARY RESEARCH
- 2.2.2.1 Key industry insights
- 2.3 MARKET SIZE ESTIMATION METHODOLOGY
- 2.3.1 BOTTOM-UP APPROACH
- 2.3.1.1 Approach 1: Company revenue estimation approach
- 2.3.1.2 Approach 2: Customer-based market estimation
- 2.3.1.3 Approach 3: Top-down approach
- 2.3.1.4 Approach 4: Primary interviews
- 2.3.1.5 Growth forecast
- 2.3.1.6 CAGR projection
- 2.3.2 TOP-DOWN APPROACH
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 MARKET SHARE ASSESSMENT
- 2.6 RESEARCH ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
- 2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 MICROFLUIDICS MARKET OVERVIEW
- 4.2 ASIA PACIFIC: MICROFLUIDICS MARKET, BY END USER AND COUNTRY (2023)
- 4.3 MICROFLUIDICS MARKET, BY REGION
- 4.4 GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing requirement for point-of-care testing
- 5.2.1.2 Rising technological advancements
- 5.2.1.3 Increasing focus on data precision and accuracy
- 5.2.1.4 Economic benefits associated with microfluidics
- 5.2.1.5 Portability with microfluidic chip miniaturization
- 5.2.1.6 Rising demand for effective sample analysis
- 5.2.2 RESTRAINTS
- 5.2.2.1 Stringent regulatory approval process
- 5.2.2.2 Integration of microfluidics into current workflow
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Emergence of 3D cell culture systems
- 5.2.3.2 Growth potential of emerging economies
- 5.2.3.3 Use of microfluidics in life sciences & pharmaceutical industries
- 5.2.4 CHALLENGES
- 5.2.4.1 Low adoption of microfluidic devices among end users
- 5.3 INDUSTRY TRENDS
- 5.3.1 E-HEALTH DIAGNOSTICS
- 5.3.2 INTEGRATION OF MICROFLUIDICS WITH 3D PRINTING
- 5.3.3 R&D INVESTMENTS FOR PRODUCT DEVELOPMENT
- 5.4 PORTER'S FIVE FORCES ANALYSIS
- 5.4.1 THREAT OF NEW ENTRANTS
- 5.4.2 THREAT OF SUBSTITUTES
- 5.4.3 BARGAINING POWER OF SUPPLIERS
- 5.4.4 BARGAINING POWER OF BUYERS
- 5.4.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.5 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.5.2 BUYING CRITERIA
- 5.6 REGULATORY LANDSCAPE
- 5.6.1 NORTH AMERICA
- 5.6.1.1 US
- 5.6.1.2 Canada
- 5.6.2 EUROPE
- 5.6.3 ASIA PACIFIC
- 5.6.3.1 Japan
- 5.6.3.2 China
- 5.6.3.3 India
- 5.6.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.7 REIMBURSEMENT SCENARIO
- 5.8 ECOSYSTEM ANALYSIS
- 5.9 VALUE CHAIN ANALYSIS
- 5.9.1 RESEARCH & DEVELOPMENT
- 5.9.2 RAW MATERIAL PROCUREMENT & MANUFACTURING
- 5.9.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES
- 5.10 SUPPLY CHAIN ANALYSIS
- 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.12 IMPACT OF GEN AI ON MICROFLUIDICS MARKET
- 5.13 PATENT ANALYSIS
- 5.13.1 PATENT PUBLICATION TRENDS FOR MICROFLUIDICS
- 5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.14 TRADE ANALYSIS
- 5.14.1 IMPORT DATA
- 5.14.2 EXPORT DATA (HS CODE 3822)
- 5.14.3 EXPORT DATA (HS CODE 8479)
- 5.15 TECHNOLOGY ANALYSIS
- 5.15.1 KEY TECHNOLOGIES
- 5.15.1.1 Biosensor elements
- 5.15.1.2 Materials science
- 5.15.1.3 Microfabrication
- 5.15.1.4 Direct-writing
- 5.15.1.5 Optofluidics
- 5.15.1.6 Acoustofluidics
- 5.15.2 COMPLEMENTARY TECHNOLOGIES
- 5.15.2.1 MEMS
- 5.15.2.1.1 Green microfluidics
- 5.15.2.1.2 Microsensors/transducers
- 5.15.3 ADJACENT TECHNOLOGIES
- 5.15.3.1 3D inkjet printing
- 5.15.3.2 Lab-on-fiber
- 5.16 KEY CONFERENCES & EVENTS
- 5.17 PRICING ANALYSIS
- 5.17.1 AVERAGE SELLING PRICE TREND, BY REGION
- 5.17.2 AVERAGE SELLING PRICE OF TOP 3 APPLICATIONS, BY KEY PLAYER
- 5.18 UNMET NEEDS/END-USER EXPECTATIONS
- 5.19 CASE STUDY ANALYSIS
- 5.19.1 CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ
- 5.19.2 CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO
- 5.19.3 CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY
- 5.20 INVESTMENT & FUNDING SCENARIO
6 MICROFLUIDICS MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 MICROFLUIDICS-BASED DEVICES
- 6.2.1 HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS TO PROPEL MARKET
- 6.3 MICROFLUIDIC COMPONENTS
- 6.3.1 MICROFLUIDIC COMPONENTS, BY TYPE
- 6.3.1.1 Microfluidic chips
- 6.3.1.1.1 Chips to account for largest share of components market
- 6.3.1.2 Flow & pressure sensors
- 6.3.1.2.1 Utilization in lab diagnostics & research applications to drive market
- 6.3.1.3 Flow & pressure controllers
- 6.3.1.3.1 Cost-effectiveness and durability to boost demand
- 6.3.1.4 Microfluidic valves
- 6.3.1.4.1 Technological advancements to support market growth
- 6.3.1.5 Micropumps
- 6.3.1.5.1 Wide usage in drug delivery and glucose injections to fuel uptake
- 6.3.1.6 Microneedles
- 6.3.1.6.1 Miniscule size and painless patch application procedure to boost demand
- 6.3.1.7 Other microfluidic components
- 6.3.2 MICROFLUIDIC COMPONENTS, BY MATERIAL
- 6.3.2.1 Silicon
- 6.3.2.1.1 High precision and durability to boost demand
- 6.3.2.2 Polymers
- 6.3.2.2.1 Polymethyl methacrylate (PMMA)
- 6.3.2.2.1.1 Durable alternative to glass to fuel uptake
- 6.3.2.2.2 Polydimethylsiloxane (PDMS)
- 6.3.2.2.2.1 Limited compatibility with specific solvents and acids to limit market adoption
- 6.3.2.2.3 Cyclic olefin copolymers
- 6.3.2.2.3.1 Low water absorption and enhanced electrical insulation properties to boost demand
- 6.3.2.2.4 Other polymers
- 6.3.2.3 Glass
- 6.3.2.3.1 High cost and brittleness to restrain market
7 MICROFLUIDICS MARKET, BY APPLICATION
- 7.1 INTRODUCTION
- 7.2 IVD
- 7.2.1 CLINICAL DIAGNOSTICS
- 7.2.1.1 Growing focus on early disease detection to drive market
- 7.2.2 POINT-OF-CARE TESTING (POCT)
- 7.2.2.1 High uptake of lab-on-a-chip technologies to fuel uptake
- 7.2.3 VETERINARY DIAGNOSTICS
- 7.2.3.1 Detection of toxins in food through LOC systems to support market growth
- 7.3 PHARMACEUTICAL & LIFE SCIENCE RESEARCH
- 7.3.1 LAB ANALYTICS
- 7.3.1.1 Proteomic analysis
- 7.3.1.1.1 Utilization of lab-on-a-chip devices for therapeutic development to drive market
- 7.3.1.2 Genomic analysis
- 7.3.1.2.1 Growing focus on NGS and digital PCR to boost demand
- 7.3.1.3 Cell-based assays
- 7.3.1.3.1 Drug screening for cross-reaction & toxicity testing to support market growth
- 7.3.1.4 Capillary electrophoresis
- 7.3.1.4.1 Growing applications for environmental monitoring and clinical diagnostics to fuel uptake
- 7.3.2 MICRODISPENSING
- 7.3.2.1 Suitability for low-viscosity applications to support market growth
- 7.3.3 MICROREACTORS
- 7.3.3.1 High uptake by leading companies for process optimization to fuel market
- 7.4 THERAPEUTICS
- 7.4.1 DRUG DELIVERY
- 7.4.1.1 Utilization of microneedles for painless and precise delivery to drive market
- 7.4.2 WEARABLE DEVICES
- 7.4.2.1 Integration of microfluidics-based wearable devices to support market growth
8 MICROFLUIDICS MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.2 HOSPITALS AND DIAGNOSTIC CENTERS
- 8.2.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED EQUIPMENT AND FOCUS ON EARLY DISEASE DIAGNOSIS TO BOOST DEMAND
- 8.3 ACADEMIC & RESEARCH INSTITUTES
- 8.3.1 INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
- 8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 8.4.1 GROWING FOCUS ON BIOMARKER & DRUG DISCOVERY TO PROPEL MARKET
9 MICROFLUIDICS MARKET, BY REGION
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 9.2.2 US
- 9.2.2.1 High healthcare expenditure and wide adoption of technologically advanced products to drive market
- 9.2.3 CANADA
- 9.2.3.1 Government funds and focus on research to support market growth
- 9.3 EUROPE
- 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 9.3.2 GERMANY
- 9.3.2.1 Growing focus on proteomics & genomics research to drive market
- 9.3.3 FRANCE
- 9.3.3.1 Favorable government support for R&D to drive market
- 9.3.4 UK
- 9.3.4.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand
- 9.3.5 ITALY
- 9.3.5.1 Innovative development of microfluidic chips to boost demand
- 9.3.6 SPAIN
- 9.3.6.1 Growth in pharmaceutical industry to fuel uptake
- 9.3.7 REST OF EUROPE
- 9.4 ASIA PACIFIC
- 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 9.4.2 CHINA
- 9.4.2.1 Growing focus on nanotechnology to drive market
- 9.4.3 JAPAN
- 9.4.3.1 High investments in academic research activities to propel market
- 9.4.4 INDIA
- 9.4.4.1 Increasing prevalence of CVD and diabetes to support market growth
- 9.4.5 AUSTRALIA
- 9.4.5.1 Rising incidence of infectious diseases to fuel uptake
- 9.4.6 SOUTH KOREA
- 9.4.6.1 Increasing R&D expenditure to drive growth
- 9.4.7 REST OF ASIA PACIFIC
- 9.5 LATIN AMERICA
- 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 9.5.2 BRAZIL
- 9.5.2.1 Increasing development of disease diagnostics kits to fuel uptake
- 9.5.3 MEXICO
- 9.5.3.1 Rising prevalence of chronic diseases to boost demand for POC testing
- 9.5.4 REST OF LATIN AMERICA
- 9.6 MIDDLE EAST & AFRICA
- 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 9.6.2 GCC COUNTRIES
- 9.6.2.1 Adoption of advanced microfluidic devices to support market growth
- 9.6.3 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
- 10.1 INTRODUCTION
- 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 10.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET
- 10.4 REVENUE ANALYSIS, 2019-2023
- 10.5 MARKET SHARE ANALYSIS, 2023
- 10.6 RANKING OF KEY MARKET PLAYERS
- 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 10.7.1 STARS
- 10.7.2 EMERGING LEADERS
- 10.7.3 PERVASIVE PLAYERS
- 10.7.4 PARTICIPANTS
- 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 10.7.5.1 Company footprint
- 10.7.5.2 Product footprint
- 10.7.5.3 Application footprint
- 10.7.5.4 End-user footprint
- 10.7.5.5 Region footprint
- 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 10.8.1 PROGRESSIVE COMPANIES
- 10.8.2 RESPONSIVE COMPANIES
- 10.8.3 DYNAMIC COMPANIES
- 10.8.4 STARTING BLOCKS
- 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 10.8.5.1 Detailed list of key startup/SME players
- 10.8.5.2 Competitive benchmarking of key emerging players/startups
- 10.9 COMPANY VALUATION & FINANCIAL METRICS
- 10.9.1 FINANCIAL METRICS
- 10.9.2 COMPANY VALUATION
- 10.10 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 10.11 COMPETITIVE SCENARIO
- 10.11.1 PRODUCT LAUNCHES & APPROVALS
- 10.11.2 DEALS
- 10.11.3 EXPANSIONS
- 10.11.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
- 11.1 KEY PLAYERS
- 11.1.1 DANAHER CORPORATION
- 11.1.1.1 Business overview
- 11.1.1.2 Products offered
- 11.1.1.3 Recent developments
- 11.1.1.3.1 Deals
- 11.1.1.3.2 Expansions
- 11.1.1.4 MnM view
- 11.1.1.4.1 Key strengths
- 11.1.1.4.2 Strategic choices
- 11.1.1.4.3 Weaknesses & competitive threats
- 11.1.2 ILLUMINA, INC.
- 11.1.2.1 Business overview
- 11.1.2.2 Products offered
- 11.1.2.3 Recent developments
- 11.1.2.3.1 Product launches & approvals
- 11.1.2.3.2 Deals
- 11.1.2.4 MnM view
- 11.1.2.4.1 Key strengths
- 11.1.2.4.2 Strategic choices
- 11.1.2.4.3 Weaknesses & competitive threats
- 11.1.3 BIOMERIEUX
- 11.1.3.1 Business overview
- 11.1.3.2 Products offered
- 11.1.3.3 Recent developments
- 11.1.3.3.1 Product launches & approvals
- 11.1.3.3.2 Deals
- 11.1.3.4 MnM view
- 11.1.3.4.1 Key strengths
- 11.1.3.4.2 Strategic choices
- 11.1.3.4.3 Weaknesses & competitive threats
- 11.1.4 THERMO FISHER SCIENTIFIC INC.
- 11.1.4.1 Business overview
- 11.1.4.2 Products offered
- 11.1.4.3 Recent developments
- 11.1.4.3.1 Product launches & approvals
- 11.1.4.3.2 Deals
- 11.1.4.3.3 Expansions
- 11.1.4.4 MnM view
- 11.1.4.4.1 Key strengths
- 11.1.4.4.2 Strategic choices
- 11.1.4.4.3 Weaknesses & competitive threats
- 11.1.5 ABBOTT LABORATORIES
- 11.1.5.1 Business overview
- 11.1.5.2 Products offered
- 11.1.5.3 MnM view
- 11.1.5.3.1 Key strengths
- 11.1.5.3.2 Strategic choices
- 11.1.5.3.3 Weaknesses & competitive threats
- 11.1.6 PARKER HANNIFIN CORP
- 11.1.6.1 Business overview
- 11.1.6.2 Products offered
- 11.1.7 SMC CORPORATION
- 11.1.7.1 Business overview
- 11.1.7.2 Products offered
- 11.1.7.3 Recent developments
- 11.1.7.3.1 Product launches
- 11.1.8 IDEX CORPORATION
- 11.1.8.1 Business overview
- 11.1.8.2 Products offered
- 11.1.8.3 Recent developments
- 11.1.9 FORTIVE
- 11.1.9.1 Business overview
- 11.1.9.2 Products offered
- 11.1.10 REVVITY, INC.
- 11.1.10.1 Business overview
- 11.1.10.2 Products offered
- 11.1.10.3 Recent developments
- 11.1.11 AGILENT TECHNOLOGIES, INC.
- 11.1.11.1 Business overview
- 11.1.11.2 Products offered
- 11.1.11.3 Recent developments
- 11.1.11.3.1 Product launches
- 11.1.11.3.2 Deals
- 11.1.11.3.3 Expansions
- 11.1.12 BIO-RAD LABORATORIES, INC.
- 11.1.12.1 Business overview
- 11.1.12.2 Products offered
- 11.1.12.3 Recent developments
- 11.1.12.3.1 Product launches
- 11.1.12.3.2 Deals
- 11.1.13 BECTON, DICKINSON AND COMPANY
- 11.1.13.1 Business overview
- 11.1.13.2 Products offered
- 11.1.13.3 Recent developments
- 11.1.13.3.1 Product launches & approvals
- 11.1.13.3.2 Deals
- 11.1.13.3.3 Expansions
- 11.1.14 F. HOFFMANN-LA ROCHE LTD.
- 11.1.14.1 Business overview
- 11.1.14.2 Products offered
- 11.1.14.3 Recent developments
- 11.1.14.3.1 Product launches & approvals
- 11.1.14.3.2 Deals
- 11.1.15 STANDARD BIOTOOLS
- 11.1.15.1 Business overview
- 11.1.15.2 Products offered
- 11.1.15.3 Recent developments
- 11.1.15.3.1 Product launches & approvals
- 11.1.15.3.2 Deals
- 11.1.16 QUIDELORTHO CORPORATION
- 11.1.16.1 Business overview
- 11.1.16.2 Products offered
- 11.1.16.3 Recent developments
- 11.1.16.3.1 Product approvals
- 11.1.16.3.2 Deals
- 11.1.16.3.3 Expansions
- 11.1.17 HOLOGIC, INC.
- 11.1.17.1 Business overview
- 11.1.17.2 Products offered
- 11.1.17.3 Recent developments
- 11.1.17.3.1 Product approvals
- 11.1.17.3.2 Deals
- 11.1.18 AIGNEP S.P.A.
- 11.1.18.1 Business overview
- 11.1.18.2 Products offered
- 11.1.18.3 Recent developments
- 11.1.19 DOLOMITE MICROFLUIDICS
- 11.1.19.1 Business overview
- 11.1.19.2 Products offered
- 11.1.19.3 Recent developments
- 11.1.19.3.1 Product launches & approvals
- 11.1.19.3.2 Deals
- 11.1.19.3.3 Other developments
- 11.1.20 ELVEFLOW
- 11.1.20.1 Business overview
- 11.1.20.2 Products offered
- 11.2 OTHER PLAYERS
- 11.2.1 NANOSTRING TECHNOLOGIES
- 11.2.2 INNOVATIVE BIOCHIPS, LLC
- 11.2.3 FLUIDIC ANALYTICS
- 11.2.4 UFLUIDIX
- 11.2.5 HORIBA
- 11.2.6 MICRONIT B.V.
- 11.2.7 EMULATE INC.
- 11.2.8 SPHERE FLUIDICS LIMITED
- 11.2.9 ZEON CORPORATION
- 11.2.10 QIAGEN N.V.
12 APPENDIX
- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 CUSTOMIZATION OPTIONS
- 12.4 RELATED REPORTS
- 12.5 AUTHOR DETAILS
